EU/3/15/1463

About

On 19 March 2015, orphan designation (EU/3/15/1463) was granted by the European Commission to Oncopeptides AB, Sweden, for melphalan flufenamide for the treatment of plasma cell myeloma.

Key facts

Active substance
Melphalan flufenamide
Disease / condition
Treatment of plasma cell myeloma
Date of first decision
19/03/2015
Outcome
Positive
EU designation number
EU/3/15/1463

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Oncopeptides AB
Västra Trädgårdsgatan 15
111 53 Stockholm
Sweden
Tel. +46 709 957 220
E-mail: karin.soderlind@oncopeptides.se

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating